<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084369</url>
  </required_header>
  <id_info>
    <org_study_id>Testosterone version1</org_study_id>
    <nct_id>NCT01084369</nct_id>
  </id_info>
  <brief_title>Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism</brief_title>
  <official_title>Phase IV: Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tameside Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tameside Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus is associated with long-term complications affecting mainly the eyes,&#xD;
      nerves and kidneys. One of the main underlying causes for this is damage to the lining of the&#xD;
      small blood vessels supplying these organs with dysfunction of the endothelium (lining of the&#xD;
      small blood vessels). Testosterone has been shown to have an effect macro (large) blood&#xD;
      vessels with limited data available on the micro (small) blood vessels. Testosterone is&#xD;
      recognised to have important effects on metabolism and vascular behaviour beyond the accepted&#xD;
      effects on secondary sexual characteristics. Physiological testosterone therapy is associated&#xD;
      with some beneficial effects on the cardiovascular system and has been used with some success&#xD;
      to treat patients with stable angina and chronic heart failure. The investigators therefore&#xD;
      propose to study the effects of testosterone replacement therapy in patients with&#xD;
      hypogonadism (low testosterone levels) on the endothelium in males with type 2 diabetes. 40&#xD;
      diabetic patients with type 2 diabetes and low testosterone levels and erectile dysfunction&#xD;
      (impotence) will be recruited into the study. All patients will receive testosterone&#xD;
      replacement therapy and 10 patients will also receive Vardenafil (a drug used to treat&#xD;
      impotence). The investigators hope to demonstrate an improvement in endothelial dysfunction&#xD;
      by assessing biochemical markers such as nitric oxide (a chemical that causes relaxation for&#xD;
      the blood vessels) and C-reactive protein (a chemical that can increase in patients with&#xD;
      diabetes) as well as the effect on weight, blood pressure, diabetes control and cholesterol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawal of sponsorship&#xD;
  </why_stopped>
  <start_date type="Actual">October 11, 2013</start_date>
  <completion_date type="Actual">September 14, 2014</completion_date>
  <primary_completion_date type="Actual">September 14, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in endothelial dependent and endothelial-independent vasodilatation</measure>
    <time_frame>30 and 54 weeks</time_frame>
    <description>Improvement in markers of endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of endothelial function</measure>
    <time_frame>54 weeks</time_frame>
    <description>Secondary efficacy variables will include changes of the following&#xD;
Availability of nitric oxide&#xD;
Endothelial inflammation as measured by CRP&#xD;
Serum levels of endothelial markers: IGF and adhesion molecules&#xD;
BMI, waist circumference, glycaemic control (HbA1c), lipid profile and blood pressure.&#xD;
Other laboratory parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone, Vardenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.&#xD;
Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable.</description>
    <arm_group_label>Testosterone, Vardenafil</arm_group_label>
    <other_name>Testosterone (NEBIDO)</other_name>
    <other_name>Vardenafil (Levitra)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 male patients with type 2 diabetes mellitus.&#xD;
&#xD;
          -  T2DM as judged by WHO criteria:&#xD;
&#xD;
               -  onset of diabetes mellitus after the age of 30 years&#xD;
&#xD;
               -  blood glucose controlled by diet or drugs other than insulin, or insulin&#xD;
                  initiated after 2 years diagnosis of diabetes&#xD;
&#xD;
               -  no history of diabetic ketoacidosis.&#xD;
&#xD;
          -  Symptomatic Hypogonadism as defined by:&#xD;
&#xD;
               -  Total testosterone below 10 nmol/l&#xD;
&#xD;
               -  Aging males' symptom score (AMS) above 36.&#xD;
&#xD;
          -  Hypogonadic men with erectile dysfunction&#xD;
&#xD;
          -  Age range- 50-80 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with uncontrolled hypertension (BP&gt;145/95 on treatment) or significant&#xD;
             hypotension. (BP&lt;100 systolic)&#xD;
&#xD;
          -  Current smokers&#xD;
&#xD;
          -  Recent myocardial infarction (&lt;6 months), unstable angina or ongoing chest pain,&#xD;
             recent (within 6 months) cardiac intervention (e.g. angioplasty, stenting or CABG) or&#xD;
             stroke.&#xD;
&#xD;
          -  Patients with clinical nephropathy (24 hr protein &gt;0.5 g or urine protein +) or&#xD;
             moderate renal failure (serum creatinine &gt;150 micromol/l).&#xD;
&#xD;
          -  History of prostate cancer or suspicion of prostate cancer on clinical examination&#xD;
&#xD;
          -  Androgen dependent carcinoma of the male mammary gland&#xD;
&#xD;
          -  Liver tumours&#xD;
&#xD;
          -  Hypersensitivity to NEBIDO or LEVITRA&#xD;
&#xD;
          -  Polycythaemia&#xD;
&#xD;
          -  General systemic illness, including cardiac, renal or hepatic insufficiency&#xD;
&#xD;
          -  Patients on nitrates will not be included in the Levitra arm.&#xD;
&#xD;
          -  History of loss of vision in one eye because of non arteritic ischaemic optic&#xD;
             neuropathy (NAION), regardless of whether this episode was in connection or not with&#xD;
             previous PDE5 inhibitor exposure.&#xD;
&#xD;
          -  Hereditary degenerative retinal disorders such as retinitis pigmentosa.&#xD;
&#xD;
          -  Clinically significant chronic haematological disease which may lead to priapism&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Significant active peptic ulceration.&#xD;
&#xD;
          -  Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and&#xD;
             indinavir is contraindicated, as they are potent inhibitors of CYP 3A4&#xD;
&#xD;
          -  Concomitant use of vardenafil with potent CYP 3A4 inhibitors ketoconazole and&#xD;
             itraconazole (oral form) is contra-indicated in men older than 75 years.&#xD;
&#xD;
          -  Patients deemed unable to comply with the requirements of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Jude, MD, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tameside Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tameside General Hospital</name>
      <address>
        <city>Ashton-under-Lyne</city>
        <state>Lancashire</state>
        <zip>OL6 9RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tameside Hospital NHS Foundatoin Trust</name>
      <address>
        <city>Ashton under Lyne</city>
        <zip>OL69RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tameside Hospital NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr Edward Jude</investigator_full_name>
    <investigator_title>Consultant Physician</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

